{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "In this multicenter, double-blinded randomized controlled trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this multicenter, double-blinded randomized controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "adults undergoing major cardiac, thoracic, or abdominal surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized to receive either gabapentin (600\u2009mg before surgery, 300\u2009mg twice daily for 2 days after surgery) or placebo"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was length of hospital stay."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 2,
        "evidence": "double-blinded"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 1,196 participants were randomized"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "596 were allocated to placebo, and 600 were allocated to gabapentin"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "hazard ratio, 1.07; 95% CI, 0.95 to 1.20; P = 0.26"
      },
      "Harms": {
        "score": 1,
        "evidence": "384 participants experienced one or more serious adverse events"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 17,
    "max_score": 25
  },
  "model": "gpt-4o"
}